Tech Company Financing Transactions
Flexus Biosciences Funding Round
Celgene, Kleiner Perkins Caufield & Byers and The Column Group participated in a $38 million Series B capital raise for Flexus Biosciences. The funding round closed on 12/19/2014.
Transaction Overview
Company Name
Announced On
12/19/2014
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series B
Investors
Proceeds Purpose
The company is now well positioned to advance its pipeline of immunotherapies and to select a clinical candidate from its IDO-1 inhibitor program in early 2015.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
75 Shoreway Road D
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Undisclosed
Website
Email Address
Overview
Founded with the mission to create new cancer therapeutics through an innovative application of unexploited insights in immunology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Terry Rosen
VP - Engineering
Steve Young
Browse more venture capital transactions:
Prev: 12/19/2014: Target Data venture capital transaction
Next: 12/19/2014: InvestX venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs